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doi:10.1016/j.ejvs.2009.06.011Abstract Objectives: Near-Infrared Spectroscopy (NIRS), suitable for dynamic measure-
ments, is not routinely used for peripheral arterial disease (PAD). We propose a dynamic
NIRS-based measurement to quantify variations in muscle metabolism in PAD.
Method: Sixty-seven consecutive PAD patients (malesZ 56, age 71.6 8.7 years) and 28 healthy
subjects (malesZ 12, age 30.4 11.9 years) were studied. An echo-colour Doppler (ECD)was per-
formedand theankleebrachial index (ABI)was calculated. Participants performedan incremental
treadmill test with NIRS probes on the gastrocnemius. Variations in oxygenated (HbO2), deoxygen-
ated (HHb), total (tHbZ HbO2þ HHb), and differential (dHbZHbO2 HHb) haemoglobin were
recorded and quantified as area-under-curve (AUC) within the range 1.7e3.0 km h1. Heart rate
was recorded, and the number of beats in the same interval was calculated (dHr).
Results: O2HbAUC, HHbAUC and dHbAUC differed between diseased and non-diseased legs
(P< 0.0001) and exhibited different patterns related to PAD severity according to the ABI value.
A compensatory heart rate increase was observed in PAD patients. Compared with the ECD
positivity for occlusions/stenoses or multiple plaques, only the receiver-operating characteristic
(ROC) analysis of dHbAUC (areaZ 0.932, P< 0.0001) showed a sensitivity/specificity of 87.6/93.4
for values 197 (LRþ LR: 13.36/0.13).
Conclusion: The dynamic NIRS-based test, quantifying muscle metabolic response according to
presence and degree of PAD, allows the evaluation of patients with walking disabilities.
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442 F. Manfredini et al.Introduction Participant enrolment: PAD patients were excluded inPeripheral arterial disease (PAD) affecting blood flow in the
lower limbs is responsible for altered oxygen delivery to
tissues and muscles during walking. Available methods or
techniques to assess the presence or severity of PAD are
performed mainly in static conditions. Otherwise, dynamic
evaluations, such as functional tests, are related to patients’
reported symptoms.
Near-infrared spectroscopy (NIRS) allows an objective
study of muscle metabolism at rest and under dynamic and
post-exercise conditions,1e6 revealing different patterns in
early O2 desaturation or low muscle O2 extraction in low-
performing populations.7e12 For PAD patients, whose perfor-
mance depends on both oxygen availability and its use, NIRS
measurements have been proposed.13e18 However, despite
the potential usefulness, its routine use remains limited for
PAD assessment.19We hypothesised that a dynamic assess-
ment of muscle metabolism (perfusion and O2 use) and
cardiovascular response during exercise might be useful for
the evaluation of patients with claudication or exertional leg
pain in order to quantify the degree of metabolic disease and
to determine the presence of PAD.
The aim of this study was to determine whether calf
deoxygenation detected by NIRS during a progressive level
test was quantifiable in a predetermined range of walking
speed, whether the score would differ in legs with PAD
according to the severity of the disease, and whether the
presence of PAD might be recognised among the legs under
study.
Subjects and Methods
Participant selection: Seventy-six consecutive patients (63
males, 13 females, age 72.1 7.6 years) affected by Fon-
taine’s second-stage PAD with stable claudication or walking
impairment were recruited for the study.
Among people attending our rehabilitation laboratory
(students nZ 18, personnel nZ 5 and relatives nZ 5), 28
healthy volunteers (12 male, 16 female; age 30.4 11.9)
were randomly approached.
All participants provided written informed consent, and
the protocol of the study was approved by the local Ethical
Committee.
PAD was previously independently diagnosed in patients
in the Vascular Surgery Department by means of clinical and
instrumental examinations. Diagnosis was performed on the
basis of a positive echo-colour Doppler (ECD) examination
(Philips iU22 Ultrasound System). The abdominal aorta;
common and external iliac; common, superficial and deep
femoral arteries; popliteal arteries and both tibial axes
were evaluated. High-resolution B-Mode imaging, com-
plemented by pulsed wave Doppler analysis for detection of
arterial obstruction, as well as peak-flow velocity for defi-
nition of critical stenosis were used according to published
standards.20 ECD examinations were carried out by four
expert vascular operators with comparable experience.
They were blinded to all other measurements.
Fontaine second-stage PAD patients were then referred
to our rehabilitation service. The written detailed reports
of the ECD examinations were also forwarded.the presence of contraindication or limitation to exercise
(e.g., unstable angina, recent surgery or myocardial infarc-
tion, cardiac disease with ventricular ejection fraction<30%
according to the reports of echocardiography examinations
and cancer), limitations of oxygen transport and extraction
(severe anaemia and myopathy) or severe walking disability
(reported claudication distance <50 m) affecting the
capacity to reach the predetermined speed during the
treadmill test.
All healthy subjects underwent a clinical examination
and were excluded based on the presence of any current or
chronic pathological condition. They also underwent an
ECD examination performed by the same expert vascular
operators.
Echo-colour Doppler report evaluation: On the basis of
the ECD report for each participant, legs were classified as
diseased or non-diseased. Legs were considered diseased
when affected by occlusion, stenosis and/or multiple-
vessel atherosclerotic irregularities, even those which did
not affect the distal flow.
AnkleeBrachial Index (ABI) measurement: All partici-
pants underwent ABI measurement according to the stan-
dard21 by means of a Doppler ultrasound device (Stereodop
448.S, Ultrasomed) with a 9.3-MHz probe and a standard
blood pressure cuff.
Severity of the disease was ranked on the basis of the
following ABI values: normal: 1e1.3; borderline 0.80e0.99;
moderate 0.50e0.79; severe: <0.50. Vessels were consid-
ered ‘not compressible’ when ABI> 1.40 or when the
procedure was interrupted at cuff pressures of 300 mmHg in
presence of painful symptoms, even if the Doppler signal at
the ankle could not be suppressed.
NIRS measurement and testing procedure: NIRS measure-
mentswereobtainedwitha continuouswave system(Oxymon
MK III Artinis Medical System, the Netherlands). The system,
consisting of two channels (two equal pulsed light sources,
two detectors avalanche photo diode and ambient light
protection), uses intensity-modulated light at a frequency of
1 MHz and laser diodes at three wavelengths (905, 850 and
770 nm) corresponding to high absorption of oxyhaemoglobin
(O2Hb) and deoxyhaemoglobin (HHb), with a power auto
sensing 110e240 V (approximately 40Watt). The light of laser
diodes is conducted from the instrument to the tissue and
back with optical glass fibres 3 m long. When near-infrared
lightpropagates throughbiological tissue, it ispartlyabsorbed
or scattered by the tissues and partly re-collected by the
detector. The intensity of the re-collected light provides
information about O2Hb and HHb concentrations as deter-
mined by spectral analysis. Additional parameters calculated
are the total haemoglobin (tHb) (the sum of O2Hb and HHb)
and the difference between O2Hb and HHb (dHb).
Skinfolds were measured at the calf by plicometry, and
NIRS sensors were then placed and secured with tape along
the medial side of the calf (medial gastrocnemius muscle).
The interoptode distance was maintained at 4 cm. Each
patient was fitted with a heart rate monitor (Sport Tester,
Polar Electro, Finland).
Testing was done in the morning in a temperature-
controlled environment. The treadmill test used to measure
patients’ performance was validated for patients with PAD
and based on level walking.22 The test was preceded by
Table 1 Characteristics of study participants.
PAD patients
(nZ 67)
Healthy subjects
(nZ 28)
Age (y) 71.6 8.7 30.4 11.9
Male sex, No. (%) 56 (87) 12 (43)
Lesion location No (%)
Aorto-iliac 12 (18) 0 (0)
Fem-pop 52 (78) 0 (0)
Infra-pop 14 (21) 0 (0)
Multiple 8 (12) 0 (0)
Risk factors, No. (%)
Diabetes 23 (34) 0 (0)
Hypertension 44 (66) 0 (0)
Hyperlipidemia 43 (64) 0 (0)
Smoking 55 (82) 5 (18)
Current smokers 7 (10) 5 (18)
Familiarity 20 (30) 0 (0)
Co-morbidities, No. (%)
Myocardial infarction 12 (18) 0 (0)
Coronary artery disease 17 (25) 0 (0)
Cerebrovascular disease 4 (6) 0 (0)
Lung disease 2 (3) 0 (0)
Lower limb
revascularisation
17 (25) 0 (0)
Therapy, No. (%)
Anticoagulants 5 (7) 0 (0)
Antiaggregants 62 (93) 0 (0)
Statins 43 (64) 0 (0)
Anthiypertensive 44 (66) 0 (0)
Beta-blockers 14 (21) 0 (0)
Continuous variables: mean SD. Categorical variables:
number (percentage). BMIZ Body Mass Index.
A NIRS-based Test for Peripheral Arteriopathy 443a 1-min warm-up at a speed of 1.5 km h1, began at
1.5 km h1; treadmill speed was increased progressively by
0.1 km h1 every 10 m. The test ended when the patient was
unable to maintain thewalking speed imposed for any reason
(fatigue, dyspnoea and claudication); this was noted as
maximal walking treadmill speed. Pain threshold speed was
also recorded when a claudication symptom was reported.
The patient’s heart rate (Hr) was recorded at rest in
a standing position and at the end of each test fraction. The
difference (dHr) between Hr recorded at 1.7 and at
3.0 km h1 was calculated.
Operators that performed NIRS measurements were
blinded to the results of all other measurements. Investi-
gators performing ABI and assisting the patients during the
treadmill test execution were not blinded to ECD reports.
Semiquantitative data obtained by the NIRS instrument
during the incremental test were analysed using the soft-
ware Oxysoft 47. Data within the range 1.7e3.0 km h1 were
transferred into an electronic spreadsheet, (Microsoft Excel
7.0) and, after normalisation to zero, analysed by statistical
software (Medcalc 8.0, Medcalc Software, Mariakerke,
Belgium) in order to calculate the area-under-curve (AUC)
and quantify the individual degree of variation for HbO2,
HHb, tHb and dHb (O2HbAUC, HHbAUC, tHbAUC and dHbAUC).
Statistical analysis
Continuous variables are expressed as mean SD or median
(range) according to normal or non-normal distribution, and
categorical variables as a percentage. The normal distribu-
tion of data was verified by the KolmogoroveSmirnov test.
The characteristics of the two groups of participants
were compared using unpaired Student’s t-tests. Differ-
ences between groups considered in the various phases of
the study were assessed by ManneWhitney U tests, Krus-
kaleWallis tests, or unpaired Student’s t-tests, as appro-
priate. A Spearman rank correlation was conducted to
evaluate the relationship between metabolic parameters
and ABI. A stepwise multivariate regression analysis was
also assessed to determine whether factors potentially
affecting the treadmill performance and/or the energetic
cost of walking (age, BMI and ABI) were independently
associated with metabolic measurements.
Receiver-operating characteristic (ROC) curves were
calculated to identify potential AUC cut-off values for NIRS-
based parameters consistent with the presence of multiple
vascular atherosclerotic lesions but which were not haemo-
dynamically significant. ECD was considered as a gold stan-
dard and the written reports of the vascular operators were
analysed.Wealso considered those legs affected bymultiple-
vessel atherosclerotic irregularities as diseased, even if the
atherosclerotic irregularities did not affect the distal flow.
A p-value of 0.05 or less was considered statistically
significant. Data were analysed using the software program
Medcalc 8.0 (Medcalc Software, Mariakerke, Belgium).
Results
Nine out of 76 PAD patients were excluded for the following
reasons: unstable angina and low ventricular ejection
fraction (nZ 3); myasthenia gravis (nZ 1); cancer underchemotherapy (nZ 1); severe anaemia (nZ 1) and severe
walking impairment in chronic stroke (nZ 2).
Sixty-seven PAD patients (56 males, 11 females, age
71.6 8.7 years) were finally enrolled into the study. All
healthy subjects recruited (nZ 28; 12 male, 16 female; age
30.4 11.9) were also enrolled into the study. The char-
acteristics of the participants are reported in Table 1.
The skin folds at the calf were less than 6 mm for all
participants. Healthy subjects were significantly younger
than PAD subjects.
The total final sample consisted of 129 diseased and 61
non-diseased legs, five of them belonging to PAD patients
but free from any vessel atherosclerotic lesion. Analyses of
the two groups were performed according to the phases of
the study.
All patients completed the test (maximal walking
treadmill speedZ 4.1 0.8 km h1); 60 PAD patients
interrupted the test for claudication symptoms (pain
threshold speedZ 3.0 0.8 km h1) and seven patients for
fatigue and dyspnoea in absence of peripheral symptoms.
Healthy subjects reached the maximal speed attainable on
the treadmill in absence of symptoms or signs of discomfort
(maximal walking treadmill speedZ 6.8 0.8 km h1).
No local or general adverse effects were reported during
NIRS measurement.
Figure 1 The procedures to collect and analyse data by incremental test with NIRS probes within the range 1.7e3.0 Km/h (a) in
a healthy subject (H) and in a PAD patient (P) are shown. Semiquantitative NIRS values after normalisation to zero (b) are analysed
by statistical software. The area-under the curve (AUC) (c) quantifies the individual degree of variation for oxyhaemoglobin (HbO2).
Table 2 Values of ABI (AnkleeBrachial Index) and metabolic parameters expressed as area-under-curve (AUC) for diseased
vs. non-diseased legs.
Diseased legs
(nZ 129)
Non-diseased legs
(nZ 61)
P-value
ABI 0.68 (0.30e0.90) 1.11 (1.0e1.2) <0.0001
O2HbAUC 229 (1733 to 590) 170 (272 to 1466) <0.0001
HHbAUC 435 (381 to 2117) 40 (804 to 404) <0.0001
dHbAUC 638 (3290 to 826) 159 (435 to 1704) <0.0001
tHbAUC 217 (452 to 1730) 270 (485 to 1373) 0.99
O2Hb, oxyhaemoglobin; HHb, deoxyhaemoglobin; DHb, difference (HbO2 HHbO2); tHb, total (HbO2þ HHbO2). Values are expressed as
median (range). P-value, ManneWhitney U test.
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Figure 2 Metabolic parameters expressed as area-under-
curve (AUC) of (a) oxyhaemoglobin (HbO2), (b) deoxy-
haemoglobin (HHbO2), (c) of their differential values
(dHbZ HbO2 HHbO2), and (d) of the total haemoglobin
(tHbZ HbO2þ HHbO2) for all of the legs under study, scattered
according to presence and/or severity of peripheral arterio-
pathy disease (PAD). Groups are significantly different
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vs. non-diseased legs
An example of the procedure to collect and analyse data is
shown in Fig. 1.
O2HbAUC, HHbAUC and dHbAUC differed significantly for
diseased and non-diseased legs, but tHbAUC did not (Table 2).
Dynamic NIRS-based measurements and severity of
disease
Considering diseased and non-diseased legs as a whole and
excluding legs with uncompressible vessels (nZ 5),
a significant relationship was observed between O2HbAUC,
HHbAUC, dHbAUC and the corresponding ABI (respectively:
rhoZ 0.566, rhoZ 0.521 and rhoZ 0.599, P< 0.0001).
In a subsequent stepwise multiple regression that took
into account as dependent parameters O2HbAUC, HHbAUC
and dHbAUC, among different parameters considered (age,
BMI and ABI), only ABI was included as an independent
parameter (respectively: R2Z 0.442, R2Z 0.320,
R2Z 0.430, P< 0.0001). Considering legs of PAD patients
and healthy subjects for all parameters but tHb, a different
pattern (P< 0.0001) was observed in relation to severity of
the disease (Fig. 2).
Dynamic NIRS-based measurements and presence
of disease
Compared to the ECD positivity, even in terms of multiple-
vessel irregularities, the ROC analysis of dHbAUC showed an
area of 0.932 (95% CI: 0.886e0.963, PZ 0.0001) with
sensitivity/specificity of 87.6/93.4 for values 197
(LRþ LR of 13.36 and 0.13, respectively). Significant, but
lower values were also observed for O2HbAUC, with an ROC
area of 0.910 (95% CI: 0.860e0.947, PZ 0.0001) and
sensitivity/specificity of 78.3/95 for values 76 (LRþ LR
of 15.92 and 0.23, respectively). The HHbAUC values had an
ROC area of 0.861 (95% CI: 0.803e0.906, PZ 0.0001) with
sensitivity/specificity of 71.3/91.8 for values >280
(LRþ LR of 8.70 and 0.31, respectively) (Fig. 3).
Dynamic NIRS-based measurements and
cardiovascular response in PAD patients vs.
healthy subjects
Hr at rest in standing position and at the end of the first
fraction (1.5 km h1) was not different between PAD
patients and healthy subjects (74 14 vs. 76 11 bmin1,
81 12 vs. 82 10 bmin1, PZ ns) while dHr was(KruskaleWallis test P< 0.0001) for all parameters except for
tHbAUC. Post-hoc analysis, different (P< 0.05) from factor n,
as follows: (1) Healthy:(3)(4)(5); (2) NormalPAD:(3)(4)(5);
(3) BorderlinePAD:(1)(2)(4)(5); (4) ModeratePAD:(1)(2)(3); (5)
SeverePAD:(1)(2)(3). Healthy: healthy legs of healthy subjects;
NormalPAD: healthy legs of PAD patients (ECD negative, Anklee
Brachial Index: 1e1.3); BorderlinePAD: legs with AnkleeBrachial
Index 0.80e0.99; ModeratePAD: legs with AnkleeBrachial Index
0.50e0.79; SeverePAD: legs with AnkleeBrachial Index <0.50.
446 F. Manfredini et al.significantly higher in PAD patients (13 7 vs. 6 4 bmin1,
P< 0.0001). dHr was not significantly different (PZ 0.10)
between PAD patients with (nZ 14) and without beta-
blocker therapy (nZ 53).
Discussion
With the use of a standardised dynamic NIRS-based test, we
detected the degree of muscle deoxygenation for the legs
of each subject that was found to be related to the severity
of the disease. We quantified this parameter to yield an
absolute value and established a cut-off for each NIRS-
based parameter consistent with the presence of multiple
vascular atherosclerotic lesions, despite a lack of haemo-
dynamic significance, according to the ECD evaluation.
Traditional exercise testing based on the subjective
patient’s reported onset of symptoms can be affected by
neuropathy, cognitive disorders, compliance or other
factors.
Since the 1990s, an abnormal decrease in muscle
oxygenation in patients with PAD has been observed when
the calf oxygenation of patients with claudication was
evaluated dynamically during exercise.13e18 However,
static or post-exercise measurements (e.g., muscle oxygen
consumption or tissue post-hypoxia re-saturation rates)
were more often assessed by NIRS.19 NIRS is not widely used
for PAD patient dynamic evaluation,19 despite its objective
assessment of muscle metabolism and its possible useful-
ness for dynamic tests in which walking performance is the
result of different factors. Such factors may include
cardiovascular system activity, collateral circulation and
peripheral extraction, all of which are able to compensate
for reduced oxygen delivery.
In order to propose a dynamic objective NIRS-based
assessment in a clinical setting, we tested a number of
subjects by means of a validated level-walking treadmill
test,22 after attaching the NIRS probes at the calf muscle.
We transformed the individual degree of variation for each
NIRS-based parameter into a score by calculating the area-
under-curve of the NIRS trace. To obtain values comparable
among subjects, we considered data within a pre-
determined range of exercise intensity. The lower limit was
set at 1.7 km h1 40 s after the start of the test to eliminate
the typical and variable early peak of O2 saturation
10
(Fig. 2a). The upper limit was fixed at 3.0 km h1, a speed
that most PAD patients can attain. It also represents a sub-
maximal walking speed per age, as well a starting level for
validated tests in claudication. By means of this method, at
a speed at which most patients were still asymptomatic,
a different AUC for all parameters but tHb was found
between diseased and non-diseased legs. Such different
metabolic patterns were related only to the parameter
reflecting the O2 delivery (ABI value). However, within the
same level of disease, a wide range of metabolic patterns is
observable (Fig. 2). We can hypothesise that under dynamicFigure 3 Receiver-operating characteristic (ROC) curve of (a)
oxyhaemoglobin (HbO2), (b) deoxyhaemoglobin (HHbO2), and
(c) of their differential values (dHbZ HbO2 HHbO2)
compared to the ECD positivity for the presence of vessel
irregularities, even those not haemodynamically significant.
A NIRS-based Test for Peripheral Arteriopathy 447conditions the muscle oxygenation might be influenced by
different factors such as collaterals, peripheral O2 extrac-
tion, cardiac function, inotropic and chronotropic response
to therapeutic agents, vessel wall stiffness and presence of
co-morbidities. These factors might be relevant even at
borderline levels of disease, where the metabolic pattern is
significantly altered in comparison to healthy legs, within
a low range of speeds (Fig. 2). On the other hand,
a parameter that showed similar levels in both PAD and in
healthy subjects was tHbAUC. In this test, which takes
a dynamic picture in an open system where peripheral
metabolism and cardiovascular function contribute to
walking performance, we also studied the heart rate
response. The rate of muscle oxygen use and the cardiac
output are determinant factors for oxygen delivery.23
Previous studies reported a reduced heart rate at peak
exercise in heart failure patients compared with normal
subjects8 and an enhanced cardiovascular response to
exercise in patients with metabolic myopathies.12 In our
study, the heart rate response was crucial for PAD patients
at an early stage of exercise, with a twofold higher heart
rate increase at low walking speed compared to healthy
subjects, an effect that was independent of beta-blocker
therapy. This compensatory response might explain the
similar level of local blood volume in the calf, described by
the parameter tHbAUC, which was observed in legs with and
without disease.
We also observed that the NIRS-based assessment
proposed for patients with PAD allowed for good discrimi-
nation of the legs with atherosclerotic lesions that were not
haemodynamically significant according to the ECD exami-
nation, revealing an abnormal dynamic response. The
parameter with the highest diagnostic capacity was dHbAUC,
which reflects both local perfusion and deoxygenation.
In a previous study, despite reproducible measurements,
NIRS was not considered useful as a diagnostic tool in
routine clinical practice, when compared to easy, inex-
pensive and accurate available methods, such as ABI or toe
systolic blood pressure.24 However, the proposed NIRS-
based method does not aim to substitute, but rather to
complete the diagnostic offering in PAD, with the potential
to simultaneously evaluate the effects of limiting or
compensatory factors on muscle perfusion.
We are aware that this preliminary study has several
limitations. The gold standard for PAD diagnosis was ECD,
which is known to have lower sensitivityespecificity than
other observed diagnostic techniques.25 Four different
operators, even with comparable experience, performed
the ECD examinations and some investigators were not
blinded to the ECD measurements. We analysed only
a localised region of a particular muscle but oxygen satu-
ration might vary within and between specific muscles.10
The selection of a range of speed for the analysis might
represent a possible bias. The reference population
included mainly legs of healthy young subjects to compare
the metabolic response of PAD patients to a definitely
normal sample. Finally, to avoid mixed patterns potentially
affected by some co-morbidities, our study excluded
patients with co-morbidities limiting oxygen transport and
extraction.
In conclusion, a dynamic NIRS-based test quantified the
muscle metabolic response that differed according to thepresence and degree of PAD. The test might be particularly
useful in a clinical setting to exclude vascular diseases in
patients with exertional leg pain without the classic clau-
dication symptoms in presence of high and unreliable ABI
for vessel calcification or borderline ABI values. In these
patients, the vascular disease and the metabolic deficit
might be unacknowledged or underestimated.
Further studies will enable us to evaluate the repro-
ducibility of the dynamic NIRS-based test, to evaluate its
diagnostic capacity on a large sample of asymptomatic and
symptomatic people and to observe the effects of training
on these proposed metabolic parameters.
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